Newtopia Reports Third Quarter 2023 Financial Results
- Achieves EBITDA Positive for first full quarter in Company history
- Decreases operating expenses by 52% year-over-year
- Improves Gross Margin (non IFRS)1 by 1,100 basis points year-over-year
- Quarterly conference call scheduled for
Nov 16, 2023 at5 pm ET
Third Quarter 2023 Financial Highlights (vs. Q3 2022):
- Revenue of
$2.43 million , as compared to$2.65 million . - Gross profit margin1 of 66%, as compared to 55%.
"Newtopia's Q3 2023 was all about profitability, as we delivered our Company's first EBITDA-positive quarter", said
Ruby continued, "During the quarter, we maintained our key innovator clients while pursuing new initiatives in both the
Revenue for the three months ended
Non-IFRS gross profit for the third quarter 2023 totaled
Operating expenses2 for the three months ended
The Company ended the third quarter 2023 with approximately
Newtopia anticipates that the Company will remain EBITDA positive in the fourth quarter.
The Company will host a conference call today at
A replay of the conference call will be available through
Newtopia is a tech-enabled habit change provider focused on disease prevention and reducing the cost of care for health insurers. As a provider of whole person care, we prevent, reverse and slow the progression of chronic disease while enriching mental health, resilience and overall human performance. Newtopia's programs leverage genetic, social and behavioral insights to create individualized prevention programs with a focus on type 2 diabetes, heart disease, stroke and weight. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. To learn more, visit newtopia.com, LinkedIn or X.
This news release contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, and forward looking statements, within the meaning of applicable
Should any factor affect Newtopia's in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Newtopia does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release, and Newtopia undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
The Company's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS"). Management uses certain non-IFRS measures, which are defined in the appropriate sections of this press release, to better assess the Company's underlying performance. These measures are reviewed regularly by management and the Company's Board of Directors in assessing the Company's performance and in making decisions about ongoing operations. In addition, we use certain non-IFRS measures to determine the components of management compensation. We believe that these measures are also used by investors as an indicator of the Company's operating performance. Readers are cautioned that these terms are not recognized IFRS measures and do not have a standardized meaning under IFRS and should not be construed as alternatives to IFRS terms, such as net income.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Gross Profit Information 1
Three Months Ended | Nine Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
$ | $ | $ | $ | ||||
Revenue | 2,434,606 | 2,653,411 | 7,440,297 | 8,052,111 | |||
Cost of revenue | (1,040,987) | (1,201,016) | (3,501,369) | (4,060,793) | |||
Gross profit | 1,393,619 | 1,452,395 | 3,938,928 | 3,991,318 | |||
Add Amortization of intangible asset | 206,514 | - | 619,537 | - | |||
Non-IFRS adjusted gross profit | 1,600,133 | 1,452,395 | 4,558,465 | 3,991,318 | |||
Gross profit margin | 57 % | 55 % | 53 % | 50 % | |||
Non-IFRS adjusted gross profit | 66 % | 55 % | 61 % | 50 % | |||
Reconciliation of Total Operating Expenses to Adjusted Operating Expenses 2
Three Months Ended | Nine Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
$ | $ | $ | $ | ||||
Total expenses | 2,167,150 | 3,700,414 | 7,316,306 | 10,098,771 | |||
Add (Subtract) | |||||||
Share-based compensation | (158,584) | (140,314) | (466,887) | (404,112) | |||
Depreciation of property and | (1,386) | (11,891) | (4,965) | (39,674) | |||
Depreciation of right-of-use asset | - | (46,192) | - | (138,579) | |||
Interest and accretion expense | (246,556) | (79,163) | (593,979) | (276,884) | |||
Interest on lease obligations | (5,221) | (17,485) | (26,784) | (60,747) | |||
Finance charges | (145,024) | (70,269) | (376,990) | (147,816) | |||
Amortization of deferred finance | (39,710) | (68,140) | (107,500) | (191,910) | |||
Foreign exchange loss (gain) | 17,302 | 5,534 | (36,791) | 28,998 | |||
Capitalized borrowing costs | - | - | - | 67,000 | |||
Impairment of right-of-use asset | - | - | - | - | |||
Loss on extinguishment of debt | (15,336) | - | (15,336) | - | |||
Debt modification | 6,380 | - | 6,380 | - | |||
Gain on settlement of related party | - | 3,111 | 7,203 | 3,111 | |||
Adjusted operating expenses | 1,579,015 | 3,275,605 | 5,700,657 | 8,938,158 | |||
EBITDA 3
Three Months Ended | Nine Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
$ | $ | $ | $ | ||||
Non-IFRS adjusted gross profit | 1,600,133 | 1,452,395 | 4,558,465 | 3,991,318 | |||
Adjusted operating expenses | (1,579,015) | (3,275,605) | (5,700,657) | (8,938,158) | |||
EBITDA | 21,118 | (1,823,210) | (1,142,192) | (4,946,840) | |||
NEWTOPIA INC.
Condensed Interim Consolidated Statements of Financial Position (Unaudited)
As at
(Expressed in Canadian Dollars)
2023 | 2022 | ||
$ | $ | ||
Assets | |||
Current assets | |||
Cash | 575,634 | 345,950 | |
Trade and other receivables | 1,774,627 | 1,557,640 | |
Contract asset | 15,330 | 190,000 | |
Prepaid expenses and deposits | 239,555 | 205,843 | |
Inventories | 117,420 | 325,571 | |
Deferred costs | 86,029 | 76,269 | |
2,808,595 | 2,701,273 | ||
Property and equipment | 5,635 | 8,052 | |
Intangible asset | 2,615,826 | 3,235,363 | |
5,430,056 | 5,944,688 | ||
Liabilities | |||
Current liabilities | |||
Trade and other payables | 1,889,258 | 2,584,039 | |
Credit facility | 4,362,850 | 4,823,545 | |
Lease obligations | 106,486 | 544,700 | |
Deferred revenue | 48,185 | 48,185 | |
Debentures | 2,550,619 | 2,409,103 | |
8,957,398 | 10,409,572 | ||
Debentures | 2,762,368 | 1,068,772 | |
11,719,766 | 11,478,344 | ||
Equity/Deficit | |||
Common shares | 49,385,725 | 47,978,992 | |
Contributed surplus | 14,073,223 | 12,861,449 | |
Deficit | (69,748,658) | (66,374,097) | |
(6,289,710) | (5,533,656) | ||
5,430,056 | 5,944,688 |
NEWTOPIA INC.
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited)
Three and Nine Months Ended
(Expressed in Canadian Dollars)
Three Months Ended | Nine Months Ended | |||||
2023 | 2022 | 2023 | 2022 | |||
$ | $ | $ | $ | |||
Revenue | 2,434,606 | 2,653,411 | 7,440,297 | 8,052,111 | ||
Cost of revenue | 1,040,988 | 1,201,016 | 3,501,663 | 4,060,793 | ||
Gross profit | 1,393,618 | 1,452,395 | 3,938,634 | 3,991,318 | ||
Operating expenses | ||||||
Technology and development | 446,504 | 1,259,596 | 1,891,276 | 2,909,996 | ||
Sales and marketing | 317,544 | 645,452 | 1,094,976 | 2,158,597 | ||
General and administrative | 814,967 | 1,370,557 | 2,714,405 | 3,869,565 | ||
Share‑based compensation | 158,584 | 140,314 | 466,887 | 404,112 | ||
Depreciation of property and | 1,386 | 11,891 | 4,965 | 39,674 | ||
Depreciation of right‑of‑use asset | ‑ | 46,192 | ‑ | 138,579 | ||
1,738,985 | 3,474,002 | 6,172,509 | 9,520,523 | |||
Other expenses (income) | ||||||
Interest and accretion expense | 246,556 | 79,163 | 593,979 | 276,884 | ||
Interest on lease obligations | 5,221 | 17,485 | 26,784 | 60,747 | ||
Finance charges | 145,024 | 70,269 | 376,990 | 147,816 | ||
Amortization of deferred finance | 39,710 | 68,140 | 107,500 | 191,910 | ||
Foreign exchange (gain)/loss | (17,302) | (5,534) | 36,791 | (28,998) | ||
Capitalized borrowing costs | ‑ | ‑ | ‑ | (67,000) | ||
Debt modification | 8,956 | ‑ | 8,956 | ‑ | ||
Loss on settlement of related party | (3,111) | ‑ | (10,314) | ‑ | ||
425,054 | 229,523 | 1,140,686 | 581,359 | |||
Net loss and comprehensive loss | (770,421) | (2,251,130) | (3,374,561) | (6,110,564) | ||
NEWTOPIA INC.
Condensed Interim Consolidated Statements of Changes in Equity (Deficit) (Unaudited)
Nine Months Ended
(Expressed in Canadian Dollars)
Common | Contributed | Deficit | Total | |||||
$ | $ | $ | $ | |||||
Balance, | 47,978,992 | 12,861,449 | (66,374,097) | (5,533,656) | ||||
Net loss and comprehensive loss | ‑ | ‑ | (3,374,561) | (3,374,561) | ||||
Share‑based compensation | ‑ | 466,887 | ‑ | 466,887 | ||||
Settlement of related party payable | ‑ | 182,451 | ‑ | 182,451 | ||||
930,218 | 537,077 | ‑ | 1,467,295 | |||||
(26,443) | 26,443 | ‑ | ‑ | |||||
Exercise of warrants | 318,065 | (59,766) | ‑ | 258,299 | ||||
Bonus Amendment Shares | 78,262 | ‑ | ‑ | 78,262 | ||||
Bonus Replacement Shares | 15,300 | 14,651 | ‑ | 29,951 | ||||
Bonus shares issued on | 91,331 | 44,031 | ‑ | 135,362 | ||||
Balance, | 49,385,725 | 14,073,223 | (69,748,658) | (6,289,710) | ||||
Balance, | 45,177,120 | 11,652,200 | (58,673,634) | (1,844,314) | ||||
Net loss and comprehensive loss | ‑ | ‑ | (6,110,564) | (6,110,564) | ||||
Share‑based compensation | ‑ | 404,112 | ‑ | 404,112 | ||||
Private Placement Offering of Units, net of issuance costs | 2,624,495 | 511,839 | ‑ | 3,136,334 | ||||
Compensation options issued to brokers | (83,230) | 83,230 | ‑ | ‑ | ||||
Adjustment of issuance costs on Debentures | ‑ | 4,733 | ‑ | 4,733 | ||||
Settlement of related party payable | ‑ | 87,121 | ‑ | 87,121 | ||||
Balance, | 47,718,385 | 12,743,235 | (64,784,198) | (4,322,578) | ||||
NEWTOPIA INC.
Condensed Interim Consolidated Statements of Cash Flows (Unaudited)
Nine Months Ended
(Expressed in Canadian Dollars)
Nine Months Ended | |||
2023 | 2022 | ||
$ | $ | ||
Cash flows used in operating activities: | |||
Net loss and comprehensive loss | (3,374,561) | (6,110,564) | |
Items not involving cash: | |||
Depreciation of property and equipment | 4,965 | 39,674 | |
Depreciation of right‑of‑use asset | ‑ | 138,579 | |
Amortization of intangible asset | 619,537 | ‑ | |
Amortization of deferred finance charges | 107,500 | 191,910 | |
Capitalized borrowing costs | ‑ | (67,000) | |
Share‑based compensation | 466,887 | 404,112 | |
Accretion expense | 353,530 | 124,184 | |
Interest on lease obligations | 26,784 | 60,747 | |
Debt modification | 8,956 | ‑ | |
Loss on settlement of related party payable | (10,314) | ‑ | |
(1,796,716) | (5,218,358) | ||
Net change in non‑cash working capital | |||
Trade and other receivables | (216,987) | (231,205) | |
Inventories | 208,151 | (260,852) | |
Prepaid expenses and deposits | (33,712) | 55,880 | |
Trade and other payables | (502,016) | 1,043,867 | |
Deferred revenue | ‑ | (10,248) | |
Contract asset/liability | 174,670 | (135,034) | |
(2,166,610) | (4,755,950) | ||
Cash flows used in investing activities | |||
Purchase of property and equipment | (2,548) | (3,829) | |
Intangible asset development costs | - | (985,349) | |
(2,548) | (989,178) | ||
Cash flows from (used in) financing activities: | |||
Credit facility withdrawals | 4,706,984 | 8,028,277 | |
Credit facility repayments | (5,167,679) | (5,478,831) | |
Credit facility financing costs | (117,260) | (81,831) | |
Repayment of lease obligations | (464,998) | (281,913) | |
Proceeds from private placement issuance of Units, net of |
1,467,295 |
3,136,334 | |
Proceeds from issuance of debenture units, net of |
1,746,201 |
‑ | |
Repayment of Debentures | (30,000) | ‑ | |
Proceeds from exercise of warrants | 258,299 | ‑ | |
2,398,842 | 5,322,036 | ||
Increase/(Decrease) in cash | 229,684 | (423,092) | |
Cash, beginning of period | 345,950 | 811,584 | |
Cash, end of period | 575,634 | 388,492 | |
___________________________________ | |
1 | Gross profit is defined as revenue, which is comprised of onboarding |
2 | Adjusted operating expenses consist of all cash-based technology, sales and marketing and administrative expenses. Adjusted operating expense is not a measure of financial performance under IFRS and should not be considered a substitute for total operating expenses, which we believe to be the most directly comparable IFRS measure. |
3 | EBITDA stands for "earnings before interest, tax, depreciation and amortization". Although a commonly used financial metric, EBITDA is not a measure of financial performance under IFRS and should not be considered a substitute for loss from operations which we believe to be the most directly comparable IFRS measure. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/newtopia-reports-third-quarter-2023-financial-results-301991352.html
SOURCE Newtopia Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman’s CEO Solomon says to watch political volatility around data centers
- Tammi Heaton Named to SIA's Global Power 150 Women in Staffing List for 12th Consecutive Year
- Roofing Expert Michael Majeski Explains Easy Exterior Upgrades With Big Impact in HelloNation
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share